Cargando…

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi

BACKGROUND: Posaconazole (POS) is a broad-spectrum triazole antifungal that exhibits potent antifungal activity against a variety of yeasts and molds. We evaluated the in vitro activities of posaconazole and comparator antifungal agents against 2,554 isolates of filamentous fungi including 2,100 Asp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castanheira, Mariana, Carvalhaes, Cecilia G, Motyl, Mary, Han, Seongah, Campbell, Havilland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776654/ http://dx.doi.org/10.1093/ofid/ofaa439.1334

Ejemplares similares

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme
por: Carvalhaes, Cecilia G, et al.
Publicado: (2021)

1161. Effectiveness of Posaconazole in the Treatment of Rare Invasive Fungal Infections: A Systematic Literature Review
por: Bernauer, Mark, et al.
Publicado: (2020)

Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)
por: Pfaller, Michael A., et al.
Publicado: (2021)

Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)
por: Pfaller, Michael A., et al.
Publicado: (2021)

1305. Antimicrobial Activity of Ceftaroline and Comparator Agents against Ceftriaxone-Non-Susceptible Streptococcus pneumoniae from the United States (2008-2020)
por: Sader, Helio S, et al.
Publicado: (2021)

347. Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017-2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents
por: Georgacopoulos, Ourania, et al.
Publicado: (2021)

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific
por: Carvalhaes, Cecilia G., et al.
Publicado: (2023)

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018)
por: Pfaller, Michael A., et al.
Publicado: (2020)

2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018
por: Pfaller, Michael A, et al.
Publicado: (2019)

1547. Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Droplet-based microfluidics platform for antifungal analysis against filamentous fungi
por: Iftikhar, Sehrish, et al.
Publicado: (2021)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Eye Infections Caused by Filamentous Fungi: Spectrum and Antifungal Susceptibility of the Prevailing Agents in Germany
por: Walther, Grit, et al.
Publicado: (2021)

In Vitro Activity of the Antifungal Azoles Itraconazole and Posaconazole against Leishmania amazonensis
por: de Macedo-Silva, Sara Teixeira, et al.
Publicado: (2013)

1148. Duration of Antibiotic Therapy in the Treatment of Bacterial Meningitis in Young Infants: A Systematic Review and Narrative Synthesis
por: Van Hentenryck, Maite, et al.
Publicado: (2021)

Dendrimer-based posaconazole nanoplatform for antifungal therapy
por: Tang, Shengzhuang, et al.
Publicado: (2021)

1229. Antimicrobial Activity of Plazomicin against Multidrug-resistant Enterobacterales: Results from 3 Years of Surveillance in Hospitals in the United States (2018–2020)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2021)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

P1148: MULTI-SITE PRE-THERAPEUTIC BIOPSIES REVEALS GENETIC HETEROGENEITY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
por: Stampe Hersby, Ditte, et al.
Publicado: (2023)

333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

1261. Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019
por: Sader, Helio S, et al.
Publicado: (2020)

1258. Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates
por: Rhomberg, Paul R, et al.
Publicado: (2020)

129. Antimicrobial Activity of Ceftazidime–avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017–2018)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

734. Trend Analysis of Oritavancin and Comparator Agents Activity against Enterococcus Causing Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran
por: Rezaianzadeh, Abbas, et al.
Publicado: (2009)

2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
por: Castanheira, Mariana, et al.
Publicado: (2023)

Anticancer and Antifungal Compounds from Aspergillus, Penicillium and Other Filamentous Fungi
por: Bladt, Tanja Thorskov, et al.
Publicado: (2013)

P1148: REAL WORLD DATA (RWD) AMONG FOLLICULAR LYMPHOMA (FL) PATIENTS IN GERMANY WITH AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY AND COMPARISON WITH CLINICAL DATA FOR MOSUNETUZUMAB
por: Marschner, N., et al.
Publicado: (2022)

1812. Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

1948. Rise of Candida auris Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against C. auris Causing Invasive Infections
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides
por: Sader, Helio S, et al.
Publicado: (2020)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
por: Altun, A., et al.
Publicado: (2014)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Structure and Synthesis of Antifungal Disulfide β-Strand Proteins from Filamentous Fungi
por: Váradi, Györgyi, et al.
Publicado: (2018)

1629. Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Posaconazole Exhibits In Vitro and In Vivo Synergistic Antifungal Activity with Caspofungin or FK506 against Candida albicans
por: Chen, Ying-Lien, et al.
Publicado: (2013)

RP5-1148A21.3 (lncRP5) exerts oncogenic function in human ovarian carcinoma: RP5-1148A21.3 promotes ovarian carcinoma progression
por: Sun, Pingping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_teu659m3jvn4r25av88rigri6u